Analyte meter protectors and methods

• US 7,897,107 B2
• Filed: 09/30/2009
• Issued: 03/01/2011
• Est. Priority Date: 12/26/2006
• Status: Active Grant

• Current Assignee: Abbott Diabetes Care Incorporated (Abbott Laboratories)
• Original Assignee: Abbott Diabetes Care Incorporated (Abbott Laboratories)
• Inventors: Strasma, Paul, Gary, Kenneth, Arbogast, Frederic, Azzano, Lawrence
• Primary Examiner(s): Alexander; Lyle A
• Assistant Examiner(s): White; Dennis M
• Application Number:
  US12/570,989
• Publication Number:
  US 20100016788A1
• Time in Patent Office: 517 Days
• Field of Search: 422/55, 422/58, 422/61, 422/68.1, 422/82.05, 422/103, 422/104
• US Class Current: 422/68.1
• CPC Class Codes: G01N 33/4875 Details of handling test elements, e.g. dispensing or storage, not specific to a particular test method test-elements per se B01L, automatic analysers G01N35/00, in-vivo analysis on the human body for medical diagnosis A61B
• CPC Class Codes: Y10S 435/817 Enzyme or microbe electrode
• CPC Class Codes: Y10T 436/144444 Glucose

Abstract

Analyte meter protectors, meters that include the same, and methods.

Claims

1. A drug delivery system, the system comprising:

a drug delivery device;

an in vitro analyte meter having an analyte test strip port, wherein the analyte meter is integrated with the drug delivery device; and

a component having an engagement feature to align and attach the component to the test strip port, wherein the component futher includes an opening sized to prevent contaminants from entering the test strip port while allowing an in vitro analyte test strip to contact the in vitro analyte meter through the opening of the component, wherein the opening is sized to provide contact across the top and bottom surfaces of the analyte test strip when the test strip is in contact with the analyte meter.

2. The drug delivery system of claim 1, wherein the drug delivery device is an insulin pump module.

3. The drug delivery system of claim 2, wherein the insulin pump module is an insulin pump controller.

4. The drug delivery system of claim 1, wherein the analyte test strip is a glucose test strip.

5. The drug delivery system of claim 4, wherein the glucose test strip analyzes glucose in a sample of no more than about 1 microliter.

6. The drug delivery system of claim 5, wherein the glucose test strip analyzes glucose in a sample of no more than about 0.5 microliter.

7. The drug delivery system of claim 5, wherein the glucose test strip analyzes glucose in a sample of no more than about 0.2 microliter.

8. The drug delivery system of claim 1, wherein the analyte test strip is a ketone test strip.